Zhong Zhao
Vorstandsvorsitzender bei ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD.
Vermögen: 130 Mio $ am 30.04.2024
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Jeffrey Soinski | M | 61 | 10 Jahre | |
Philip R. Preuss | M | 46 | 15 Jahre | |
Yang Xie | M | 54 | 6 Jahre | |
James Cullen | M | 81 | 10 Jahre | |
Zheng Li | M | 46 | 5 Jahre | |
Nabeel Subainati | M | 41 | 4 Jahre | |
Quan Wei Yuan | M | 46 | 3 Jahre | |
Hui Wang | M | 51 | 8 Jahre | |
Himanshu Patel | M | 63 | 17 Jahre | |
Yun Qiu | F | 60 | 3 Jahre | |
Hong Ze Liang | M | 53 | 3 Jahre | |
Tamara Elias | M | 53 | 5 Jahre | |
James McElwee | M | 72 | 13 Jahre | |
Jian Ji | M | 54 | 3 Jahre | |
Ning Pan | M | 58 | 5 Jahre | |
Tao Liu | M | 44 | 2 Jahre | |
Dong Fang Li | M | 36 | 2 Jahre | |
Thomas Lawson | M | - | 8 Jahre | |
Hong Bo Wang | F | 35 | 3 Jahre | |
Sau In Kwan | F | - | 2 Jahre | |
Corey Gibbs | M | - | 11 Jahre | |
Jaafer Golzar | M | - | 6 Jahre | |
Da Song Wang | M | 55 | 4 Jahre | |
Changan Ma | M | - | 1 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Rick Anderson | M | 63 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 2 Jahre |
David H. Bergstrom | M | 70 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 1 Jahre |
Jordan P. Karp | M | 57 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
Donald W. Fallon | M | 69 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
Christopher Barys | M | 57 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 6 Jahre |
Eric Rowinsky | M | 67 |
The Johns Hopkins University School of Medicine
| 8 Jahre |
Peter Fasolo | M | 61 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | - |
Dennis O. Driver | M | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 6 Jahre |
Nancy J. McLane | F | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 7 Jahre |
Campbell D. K. Rogers | M | 62 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 6 Jahre |
Robert Greenberg | M | 56 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Mark Pomeranz | M | 63 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 9 Jahre |
Christian M. Spaulding | M | 68 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | - |
Kai Cheong Cheung | M | 49 | 1 Jahre | |
Dennis Genito | M | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 5 Jahre |
Zachary Sopcak | M | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 1 Jahre |
David-Alexandre C. Gros | M | 51 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Tyler Binney | M | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 10 Jahre |
Tammy Leitsinger | F | - |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 9 Jahre |
Zhao Renbin | M | 55 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Chun Hui Men | M | 57 | 1 Jahre | |
Hai Lu | M | 53 | - | |
Yigong Shi | M | 57 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Vance Vanier | M | - |
The Johns Hopkins University School of Medicine
| 4 Jahre |
Robert W. Croce | M | 82 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 13 Jahre |
David P. Nowotnik | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 4 Jahre |
Kevin D. Cordell | M | 58 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 4 Jahre |
J. Patrick Richardson | M | 64 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 3 Jahre |
Valerie D. Riddle | M | 63 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | - |
William Pinon | M | 60 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 1 Jahre |
Michael J. Voss | M | 61 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 4 Jahre |
Peter David Suzdak | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 Jahre |
Joseph Klein | M | 62 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 7 Jahre |
David P. Wright | M | 75 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
David Savello | M | 78 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
Mark J. Schoenebaum | M | 51 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Steven Harr | M | 53 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Seth Fischer | M | 68 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 4 Jahre |
Edward Benz | M | 78 |
The Johns Hopkins University School of Medicine
| 5 Jahre |
John McGrath | M | 64 |
Cordis Corp.
Cordis Corp. Medical SpecialtiesHealth Technology Cordis Corp. develops and manufactures devices for interventional vascular medicine and electrophysiology. The firm's products include guidewires, balloons, forceps, catheters, and stents to treat a variety of circulatory system problems including coronary artery disease and cerebral aneurysms. The company was founded by William P. Murphy Jr. in 1959 and is headquartered in Milpitas, CA. | 9 Jahre |
Francesca M. Cook | F | 58 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 2 Jahre |
Josh Bilenker | M | 52 |
The Johns Hopkins University School of Medicine
| 3 Jahre |
Nicholas Landekic | M | 65 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | 5 Jahre |
Jie Liang | F | 40 | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 50 | 73,53% |
China | 18 | 26,47% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Zhong Zhao
- Persönliches Netzwerk